BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8879679)

  • 1. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
    Szepeshazi K; Schally AV; Halmos G; Szoke B; Groot K; Nagy A
    Breast Cancer Res Treat; 1996; 40(2):129-39. PubMed ID: 8879679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
    Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
    Szepeshazi K; Schally AV; Juhasz A; Nagy A; Janaky T
    Anticancer Drugs; 1992 Apr; 3(2):109-16. PubMed ID: 1388062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
    Szepeshazi K; Schally AV; Nagy A
    Breast Cancer Res Treat; 1999 Aug; 56(3):267-76. PubMed ID: 10573117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
    J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
    Milovanovic SR; Radulovic S; Schally AV
    Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
    Pinski J; Schally AV; Yano T; Szepeshazi K; Halmos G; Groot K; Comaru-Schally AM; Radulovic S; Nagy A
    Prostate; 1993; 23(2):165-78. PubMed ID: 8378189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
    Kovacs M; Schally AV; Csernus B; Busto R; Rekasi Z; Nagy A
    J Neuroendocrinol; 2002 Jan; 14(1):5-13. PubMed ID: 11903807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
    Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
    Schally AV; Redding TW; Comaru-Schally AM
    Med Oncol Tumor Pharmacother; 1984; 1(2):109-18. PubMed ID: 6242477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
    Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.